dr. S.F. Oosting

No picture available
E-mail:
s.oosting umcg.nl

Research

Publications
  1. A randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non- clear cell renal cell carcinoma (SUNIFORECAST)

    IAGN, Bergmann, L., Grimm, M. O., Boleti, E. B., Panic, A., Gruellich, C., Bedke, J., Ahrens, M., Lorch, A., Negrier, S., Ravaud, A., Retz, M., Boegemann, M., Ivanyi, P., Siemer, S., Bathelemy, P., Rottey, S., Maroto, P., Oosting, S., Hartmann, A. & Escudier, B., 2019, In : Oncology Research and Treatment. 42, p. 285 1 p.

    Research output: Contribution to journalMeeting AbstractAcademic

  2. Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma

    Loriot, Y., Sternberg, C. N., Castellano, D., Oosting, S. F., Dumez, H., Huddart, R., Vianna, K., Alonso Gordoa, T., Skoneczna, I., Fay, A. P., Nolè, F., Massari, F., Brasiuniene, B., Maroto, P., Fear, S., Di Nucci, F., de Ducla, S. & Choy, E., Oct-2020, In : European Journal of Cancer. 138, p. 202-211 10 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

    KEYNOTE-048 Investigators, Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., Fuereder, T., Hughes, B. G. M., Mesía, R., Ngamphaiboon, N., Rordorf, T., Wan Ishak, W. Z., Hong, R-L., González Mendoza, R., Roy, A., Zhang, Y., Gumuscu, B., Cheng, J. D., Jin, F., Rischin, D. & Oosting, S. F., 23-Nov-2019, In : The Lancet. 394, 10212, p. 1915-1928 14 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy

    Stelwagen, J., Lubberts, S., Steggink, L. C., Steursma, G., Kruyt, L. M., Donkerbroek, J. W., van Roon, A. M., van Gessel, A. I., van de Zande, S. C., Meijer, C., Grafin zu Eulenburg, C. H., Oosting, S. F., Nuver, J., Walenkamp, A. M. E., Jan de Jong, I., Lefrandt, J. D. & Gietema, J. A., 14-Sep-2020, In : British Journal of Cancer. 9 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. Management of immune checkpoint inhibitor-induced polymyalgia rheumatica

    van der Geest, K. S. M., Sandovici, M., Rutgers, A., Hiltermann, T. J. N., Oosting, S. F., Slart, R. H. J. A. & Brouwer, E., 4-Sep-2020, In : Annals of the Rheumatic Diseases. 2 p.

    Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

View all (106) »

Activities
  1. European Society for Medical Oncology (ESMO) , Lugano , Switzerland. (External organisation)

    S. F. Oosting (Member)
    2019

    Activity: MembershipMembership of committeeAcademic

  2. European Society for Medical Oncology (ESMO) , Lugano , Switzerland. (External organisation)

    S. F. Oosting (Member)
    2019

    Activity: MembershipMembership of committeeAcademic

  3. European Society for Medical Oncology (ESMO) , Lugano , Switzerland. (External organisation)

    S. F. Oosting (Member)
    20182019

    Activity: MembershipMembership of committeeAcademic

View all (7) »

ID: 393538